Data Presented at ACC.26 Demonstrate Benefits of iRhythm's Zio Ambulatory ECG Portfolio

Company also launches new digital education platform for clinicians

Mar. 30, 2026 at 12:44pm

Got story updates? Submit your updates here. ›

iRhythm Holdings, Inc. announced results from three retrospective analyses presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessions that add to the growing body of clinical evidence supporting the benefits of its Zio ambulatory ECG monitoring service across patient populations. The data provide insights into the timing and incidence of clinically relevant arrhythmias and highlight opportunities to improve care for patients along the cardiovascular-kidney-metabolic (CKM) continuum. iRhythm also highlighted its leadership in advancing AI in cardiology and announced the launch of iRhythm Academy, a clinician education platform.

Why it matters

The data presented at ACC.26 build on prior real-world evidence demonstrating that arrhythmias are common, early, and often silent across cardiometabolic patient populations. These findings highlight the value of targeted rhythm monitoring in patient populations at higher risk for arrhythmia and the opportunity for earlier detection and diagnosis.

The details

Two abstracts presented at ACC.26 reported the results of retrospective analyses of the incidence of arrhythmias in patients across the CKM disease continuum. The studies found that clinically actionable arrhythmias were more commonly identified in patients with chronic kidney disease (CKD), with or without diabetes. Another study found that higher body weight was associated with greater likelihood of atrial fibrillation detection.

  • The data were presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessions in New Orleans, March 28–30, 2026.
  • iRhythm also announced the launch of iRhythm Academy, a clinician education platform, in 2026.

The players

iRhythm Holdings, Inc.

An American digital health care company that creates solutions to detect, predict, and prevent disease using wearable biosensors and cloud-based data analytics.

Mintu Turakhia, MD, MS

Chief Medical and Scientific Officer and EVP, Advanced Technologies at iRhythm, and Clinical Professor of Medicine at Stanford University.

Got photos? Submit your photos here. ›

What they’re saying

“The primary barrier to impact is no longer technical development or model performance — most AI across diagnostics, clinical decision support, and other domains work well. We need to think of these tools not as point solutions or standalone tests, but rather as critical clinical infrastructure and integrated systems that are safely and responsibly deployed.”

— Mintu Turakhia, MD, MS, Chief Medical and Scientific Officer and EVP, Advanced Technologies at iRhythm, and Clinical Professor of Medicine at Stanford University

What’s next

iRhythm also announced an upcoming update to the MyZio mobile app, which supports patients throughout their ECG monitoring journey with Zio, with the addition of Spanish-language functionality to support patient accessibility.

The takeaway

The data presented at ACC.26 highlight the high prevalence of clinically actionable arrhythmias across the cardiovascular-kidney-metabolic (CKM) continuum, emphasizing the value of targeted rhythm monitoring in patient populations at higher risk. This underscores the opportunity for earlier detection and diagnosis of arrhythmias, which can lead to improved patient outcomes.